Naomi S (Haas) Balzer MD
Genitourinary Oncology, Hematologic Oncology, Melanoma
Director, Prostate and Kidney Cancer Program; Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Join to view full profile
3400 Civic Center BlvdPhiladelphia, PA 19104
Phone+1 215-615-5858
Fax+1 215-349-8144
Dr. Balzer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Abington Memorial HospitalResidency, Internal Medicine, 1985 - 1988
Northeast Ohio Medical UniversityClass of 1985
Certifications & Licensure
PA State Medical License 1986 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsAdvanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.Rana R McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges
CA. 2025-12-13 - Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients.Taylor B Crawford, Maliha Tayeb, Emanuel Barrett, Tara Al-Saleem, Pranavi Kondam
Medrxiv. 2025-08-15 - 20 citationsFinal Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal C...Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson Jr, Vivek Narayan
Journal of Clinical Oncology. 2024-11-20
Press Mentions
- Adjuvant Pembrolizumab Shows Sustained Survival Benefit in Renal Cell Carcinoma at 5 Years - Naomi Balzer-HaasJune 10th, 2025
Three Kidney Cancer Experts to Receive Awards at 2024 IKCS: North AmericaSeptember 27th, 2024
Presents State of the Science SummitSeptember 20th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
